Key Highlights
- Third quarter 2026 net loss was $24.4 million, compared with $26.3 million a year earlier.
- Cash, cash equivalents and short-term investments totaled $142.6 million at September 30, 2026.
- The FORTIFY Phase 1b trial plans to enroll up to 102 patients across three cohorts.
- Interim FORTIFY data are expected in 2027.
Pliant Therapeutics (NASDAQ:PLRX) provided a corporate update and reported third quarter 2026 financial results on November 12, 2026. The South San Francisco, California clinical-stage biotechnology company is developing integrin-based therapeutics, including an oral oncology candidate and a drug delivery platform. The quarter's update centered on enrollment in the FORTIFY trial, new preclinical delivery data and changes to the company's Leadership team. Operating costs declined from the prior year, and the net loss narrowed modestly.
FORTIFY Trial Enrollment and Design
FORTIFY is a Phase 1a and 1b open-label, dose-escalation and indication expansion trial of PLN-101095, an oral small-molecule dual inhibitor of avß8 and avß1 integrins. The drug is designed to block TGF-ß activation in the tumor environment, and it is being tested in combination with pembrolizumab in patients with immune checkpoint inhibitor-refractory advanced or metastatic solid tumors.
The Phase 1b portion will enroll up to 102 patients across three cohorts, including non-small cell lung cancer, clear cell renal cell carcinoma and tumors with high tumor mutational burden. Patients receive PLN-101095 as monotherapy for 14 days before pembrolizumab is added. Pliant said enrollment is progressing ahead of schedule, with active sites in the United States and Spain and additional countries expected to be added in the coming months. Interim data are expected in 2027.
Platform Work and Presentations
Pliant presented Phase 1 biomarker data and mechanism-of-action findings from the program at the Society for Immunotherapy of Cancer annual meeting. The company said earlier biomarker signals were consistent with its proposed mechanism, though the findings remain early and drawn from a limited patient group.
The company also reported cross-species preclinical data showing selective delivery of siRNA payloads to tissues outside the liver using its integrin-mediated delivery platform. Chief Executive Bernard Coulie said the company will provide a comprehensive overview of the program in the coming months, as it weighs potential therapeutic applications and paths forward for the platform.
Leadership, Expenses and Cash
Pliant appointed David Raben, M.D., as chief medical officer and Craig Blanchette, Ph.D., as senior vice president of research, with a focus on RNAi work. The release presents these appointments as part of a strengthened leadership team.
The net loss for the quarter was $24.4 million, compared with $26.3 million for the prior-year quarter. The company said the decrease was driven mainly by lower operating expenses following the termination of bexotegrast development in idiopathic pulmonary fibrosis in 2025, along with lower personnel costs, including stock-based compensation, from reduced headcount. Cash, cash equivalents and short-term investments totaled $142.6 million, which the company expects to fund operations into mid-2028.
Final Word
The third quarter shows Pliant narrowing its loss through a smaller cost base while advancing FORTIFY toward its 2027 interim data and exploring its delivery platform in preclinical work. The company's cash runway extends into mid-2028, according to its release. The results of the FORTIFY study and the platform's preclinical findings will determine which directions the company pursues after the current phase of development.






Please wait processing your request...